Literature DB >> 25158669

Torsades de pointes induced by the concomitant use of ivabradine and azithromycin: an unexpected dangerous interaction.

Giuseppe Cocco1, Paul Jerie.   

Abstract

A 68-year-old man had a cardiac syncope. He was known to have a long QT-interval and was treated with ivabradine for paroxysmal sinusal tachycardia. In the last 5 days, azithromycin had been prescribed for sinusitis. An electrocardiogram showed torsades de pointes (TdP). Azithromycin is known to prolong the QT-interval. Ivabradine does not affect the QT-interval but has a conditional risk of TdP when taken with other drugs that block its metabolic breakdown. This case presents the specific problem of a patient with long QT who received two medications, which may interact and prolong the QT.

Entities:  

Mesh：

Substances：

Year:  2015        PMID： 25158669     DOI： 10.1007/s12012-014-9274-y

Source DB:  PubMed          Journal:  Cardiovasc Toxicol        ISSN： 1530-7905            Impact factor:   3.231


  11 in total

1.  Performance of Machine Learning Algorithms for Qualitative and Quantitative Prediction Drug Blockade of hERG1 channel.

Authors:  Soren Wacker; Sergei Yu Noskov
Journal:  Comput Toxicol       Date:  2017-05-13

2.  Acute on Chronic Ivabradine Overdose: a Case Report.

Authors:  Kevin Maskell; Adele Tse; Carl E Wolf; Michelle Troendle
Journal:  J Med Toxicol       Date:  2016-02-08

Review 3.  Pharmacologic Management for Ventricular Arrhythmias: Overview of Anti-Arrhythmic Drugs.

Authors:  John Larson; Lucas Rich; Amrish Deshmukh; Erin C Judge; Jackson J Liang
Journal:  J Clin Med       Date:  2022-06-06       Impact factor: 4.964

Review 4.  Heart rate reduction in coronary artery disease and heart failure.

Authors:  Roberto Ferrari; Kim Fox
Journal:  Nat Rev Cardiol       Date:  2016-05-26       Impact factor: 32.419

5.  hERG potassium channel inhibition by ivabradine may contribute to QT prolongation and risk of torsades de pointes.

Authors:  Jules C Hancox; Dario Melgari; Christopher E Dempsey; Kieran E Brack; John Mitcheson; G André Ng
Journal:  Ther Adv Drug Saf       Date:  2015-08

6.  Protective Effects of Carvedilol and Vitamin C against Azithromycin-Induced Cardiotoxicity in Rats via Decreasing ROS, IL1-β, and TNF-α Production and Inhibiting NF-κB and Caspase-3 Expression.

Authors:  Nagla A El-Shitany; Karema El-Desoky
Journal:  Oxid Med Cell Longev       Date:  2016-05-05       Impact factor: 6.543

Review 7.  The Role of Ivabradine in the Management of Angina Pectoris.

Authors:  Alessandra Giavarini; Ranil de Silva
Journal:  Cardiovasc Drugs Ther       Date:  2016-08       Impact factor: 3.727

8.  Ivabradine toxicity: A case report and review.

Authors:  Kofi Osei; Tuncay Taskesen; Jennifer Goerbig-Campbell; Troy Hounshell
Journal:  HeartRhythm Case Rep       Date:  2020-01-07

9.  hERG potassium channel blockade by the HCN channel inhibitor bradycardic agent ivabradine.

Authors:  Dario Melgari; Kieran E Brack; Chuan Zhang; Yihong Zhang; Aziza El Harchi; John S Mitcheson; Christopher E Dempsey; G André Ng; Jules C Hancox
Journal:  J Am Heart Assoc       Date:  2015-04-24       Impact factor: 5.501

10.  Ivabradine is as effective as metoprolol in the prevention of ventricular arrhythmias in acute non-reperfused myocardial infarction in the rat.

Authors:  Mariusz Marciszek; Aleksandra Paterek; Marta Oknińska; Urszula Mackiewicz; Michał Mączewski
Journal:  Sci Rep       Date:  2020-09-14       Impact factor: 4.379
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.